

Gian Luca Rampioni Vinciguerra Curriculum Vitae

Rome, 25/04/2022

Education

- **From 11/2017 - 12/2020. PhD Program in Oncology, University of Rome "La Sapienza", Italy.**
Final Dissertation entitled: "The role of p27 in the response to CDK-inhibitors in KRAS mutated colorectal cancer".
Supervisor: Prof. Andrea Vecchione. *Final degree mark: cum laude.*
Hosting institutions:
1/2020 - 12/2020. Laboratory of Dr. Carlo M. Croce, Department of Cancer Biology and Genetics. The Ohio State University, Columbus (OH), USA.
11/2017 - 1/2020. Laboratory of Dr. Gustavo Baldassarre, Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
- **07/2012 - 07/2017. Residency Program in Pathology, Faculty of Pharmacy and Medicine, University of Rome "La Sapienza", Italy.** Thesis entitled: "Role of miR-9 in the response to radiotherapy and EGFR-inhibitors in head and neck squamous cell carcinoma".
Supervisor: Prof. Andrea Vecchione. *Final degree mark: 70/70 cum laude.*
Hosting institutions:
01/2017 - 07/2017. Laboratory of Dr. Gustavo Baldassarre, Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
07/2012 - 01/2017. UOC Anatomia Patologica, Santo Andrea Hospital, Rome, Italy.
- **10/2005 - 07/2011. Master's degree in Medicine and Surgery, Faculty of Medicine and Psychology, University of Rome "La Sapienza", Italy.** Thesis entitled "microRNA expression profiling of preneoplastic lesions of the breast".
Supervisor: Prof. Andrea Vecchione. *Final degree mark: 110/110 cum laude.*
- **09/2000 - 07/2005. High school diploma in Classical Studies, Liceo Ginnasio Statale G.Mameli, Rome, Italy.** *Final degree mark: 100/100.*

Appointments

- **From 12/2020 (current position). Postdoctoral Researcher.** Department of Cancer Biology and Genetics. The Ohio State University, Columbus (OH), USA.
Supervisor: Prof. Carlo M. Croce.
- **From 07/2017 - 10/2017. Fellow.** Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, National Cancer Institute, Aviano, Italy.
Supervisor: Dott. Gustavo Baldassarre.

Job Related Skills

Autopsy technique, human histopathology, ffpe tissue preparation, H&E, immunohistochemical staining, light and confocal microscopy.

Cellular transfection/transduction, DNA/RNA extraction and electrophoresis, PCR, qRT-PCR, protein extraction (total or differential lysis), immunoprecipitation, chromatin-immunoprecipitation, immunofluorescence, WB analysis, luciferase assay.

Cell cultures and techniques of cellular biology for analysis of in vitro proliferation (growth curves, kill curve, colony assay, MTS assay, FACS analysis, soft agar assay, inclusion in 3D-matrix), bacterial transformation, plasmid preparation, gene cloning.

Handling of immunodeficient mice (nude, NOD/SCID and NSG mice) and GEMM murine models. Injection techniques (intraperitoneal, subcutaneous), drug administration, surgical procedures and murine histopathology.

Research Activities

- **From 2013 – 2017 Pathology Residency Program.** I focused on the possibility to stratify outcome of patients affected by different solid tumors according to the histological features. In particular, I studied the distribution of ALK/ROS1 translocation respect to the age of lung cancer patients (Scarpino, Rampioni Vinciguerra et al. Lung Cancer 2016) and the use of immunohistochemical staining as a reliable test to identify ALK overexpressing tumors in routinary histological analysis (Rampioni Vinciguerra et al., Virchow Arch. 2017). I carried out an experimental thesis, actively contributing to the study of miR-9 in head and neck squamous cell carcinoma response to radiotherapy and EGFR-inhibitors (Citron et al. EMBO Mol Med 2021).
- **From 2017 – 2020 PhD in Oncology Program.** I carried on a project aiming to define predictive markers of resistance to CDK4/6 kinase-inhibitors in colorectal cancer (Rampioni Vinciguerra et al. CDDIS 2021), (Rampioni Vinciguerra et al. Frontiers in Oncol 2022, *article in press*). In this context, I studied the possible role of p27kip1 as a marker of resistance to Palbociclib (Rampioni Vinciguerra et al. Cell Div. 2019). I also contributed to other studies focusing on the molecular mechanisms of oncogenesis and resistance to oncological therapies, particularly in breast cancer (Citron et al. Cancer Res. 2020) and ovarian cancer (Califano D, Gallo D, Rampioni Vinciguerra et al. Cancers 2021), (Sonogo M et al. Science Advances 2019), (Sonogo M et al. Cells 2019).
- **From 2021 – current position Post-Doctoral Researcher.** At the Ohio State University (USA), in Dr. Carlo M. Croce's Lab, I am currently carrying on two different projects, investigating the role of microRNAs in the cisplatin resistance of lung cancer (Rampioni Vinciguerra et al. *article in preparation*) and the contribution of microRNA-15a in the evolution of pancreatic cancer.

Society memberships and Scientific Recognition

- Member of American Association for Cancer Research (AACR)
- Member of European Association for Cancer Research (EACR)
- Member of Societa' Italiana Cancerologia (SIC)
- Member of Societa' Italiana Anatomia Patologica e Citologia (SIAPeC)

- Guest Editor of "Catch me if you can: cellular plasticity in tumor progression and drug resistance" Frontiers in Cell and Developmental Biology (IF 6.684)
- Reviewer Board of Frontiers in Bioscience – Landmark (IF 4.009)
- Peer Reviewer for: Molecular Cancer (IF 27.401), Cancers (IF 6.639), Diagnostics (IF 3.706)

Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
International Papers	23	Scopus	2013	2022
Total Impact factor	121.27			
Total Citations	220			
Average Citations per Product	9.6			
Hirsch (H) index	8			
Normalized H index*	0.8			

*H index divided by the academic seniority.

Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

First Author/Corresponding Author:

- 1. Evaluation of angiogenesis-related genes as prognostic biomarkers of bevacizumab treated ovarian cancer patients: Results from the phase iv mito16a/mango ov-2 translational study**
 Califano D, Gallo D, Rampioni Vinciguerra GL, ...Pignata S, Baldassarre G.
 Cancers, 2021, 13(20), 5152 (IF 6.639, Citations 1)
- 2. p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer.**
 Rampioni Vinciguerra GL, Dall'Acqua A, Segatto I, Vecchione A, Belletti B, Baldassarre G.
 Cell Death and Disease, 2021, 12(10), 951 (IF 8.469, Citations 0)
- 3. p27kip1 at the crossroad between actin and microtubule dynamics.**
 Rampioni Vinciguerra GL, Citron F, Segatto I, Belletti B, Vecchione A, Baldassarre G.
 Cell Division, 2019, 14(1), 2 (IF 3.667, Citations 9)
- 4. Pathologist second opinion significantly alters clinical management of pT1 endoscopically resected colorectal cancer.**
 Rampioni Vinciguerra GL, Antonelli G, Citron F, Berardi G, Angeletti S, Baldassarre G, Vecchione A, Di Giulio E, Pillozzi E.
 Virchows Arch. 2019 jun 17. (IF 2.906, Citations 4)
- 5 Oncocytic variant of medullary thyroid carcinoma: A rare case of sporadic multifocal and bilateral RET wild-type neoplasm with revision of the literature.**
 Rampioni Vinciguerra GL, Noccioli N, Cippitelli C, ... Capoluongo E, Bartolazzi A.
 Rare Tumors, 2016, 8(4), pp. 166–168, 6537 (JCI 0.14, Citations 8)
- 6 Optimized immunohistochemistry using the DSF3 antibody provides a reliable test for identification of ALK-positive lung adenocarcinomas**
 Rampioni Vinciguerra GL, Scarpino S, Pini B, ... Fochetti F, Ruco L.
 Virchows Archiv, 2017, 471(1), pp. 123–127 (IF 2.936, Citations 4)
- 7 Transitional cell carcinoma of the retrorectal space arisen in tailgut cyst: A case report and review of the literature**
 Rampioni Vinciguerra GL, Mercantini P, La Torre M, ... Ziparo V, Vecchione A.

Co-Author:

1. **miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC**
Citron F, Segatto I, Musco L, Pellarin I, Rampioni Vinciguerra GL, ... Belletti B, Baldassarre G.
EMBO Molecular Medicine, 2021, 13(7), e12872 (IF 12.137, Citations 4)
2. **CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.**
Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra GL, Dall'Acqua A, Bomben R, Perin T, ... Belletti B, Baldassarre G.
J Pathol. 2020 Nov 3 (IF 7.996, Citations 2)
3. **Downregulation of miR-223 expression is an early event during mammary transformation and confers resistance to CDK4/6 inhibitors in luminal breast cancer.**
Citron F, Segatto I, Rampioni Vinciguerra GL, Musco L, Russo F, Mungo G, D'Andrea S, Mattevi MC, Perin T, Schiappacassi M, Massarut S, Marchini C, Amici A, Vecchione A, Baldassarre G, Belletti B.
Cancer Res. 2020 Mar 1;80(5):1064-1077 (IF 12.701, Citations 26)
4. **TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.**
Sonego M, Poletto E, Pivetta E, Nicoloso MS, Pellicani R, Rampioni Vinciguerra GL, Citron F, Sorio R, Mongiat M, Baldassarre G.
Cells. Dec 2019. 9, 1: E6. (IF 4.366, Citations 7)
5. **Usp1 links platinum resistance to cancer cell dissemination by regulating snail stability.**
Sonego M, Pellarin I, Costa A, Rampioni Vinciguerra GL, Coan M, Kraut A, D'andrea S, Dall'acqua A, Castillo-Tong Dc, Califano D, Losito S, Spizzo R, Couté Y, Vecchione A, Belletti B, Schiappacassi M, Baldassarre G.
Sci Adv. 2019 May. 8;5(5). (IF 13.117, Citations 42)
6. **Stathmin is required for normal mouse mammary gland development and Δ16HER2-driven tumorigenesis.**
Segatto I, De Marco Zompit M, Citron F, D'Andrea S, Rampioni Vinciguerra GL, Perin T, Berton S, Mungo G, Schiappacassi M, Marchini C, Amici A, Vecchione A, Baldassarre G and Belletti B.
Cancer Res. 2019 Jan 15;79(2): 397-409. (IF 9.727, Citations 11)
7. **Sleeping beauty genetic screen identifies miR-23b:BTBD7 gene interaction as crucial for colorectal cancer metastasis.**
Grisard E, Coan M, Cesaratto L, Rigo I, Zandonà L, Paulitti A, Andreuzzi E, Rampioni Vinciguerra GL, Poletto E, (...), Baldassarre G, Mongiat M, Spizzo R, Nicoloso MS.
EBioMedicine. 2019 Aug;46:79-93. (IF 5.736, Citations 8)
8. **Mice with reduced expression of the telomere-associated protein ft1 develop p53-sensitive progeroid traits.**
La Torre M, Merigliano C, Burla R, Mottini C, Zanetti G, Del Giudice S, Carcuro M, Virdia I, Bucciarelli E, Manni I, Rampioni Vinciguerra GI, ... Verni F, Soddu S, Gatti M, Saggio I.
Aging Cell. 2018 Aug;17(4):e12730. (IF 7.346, Citations 7)
9. **Exploring the role of fallopian ciliated cells in the pathogenesis of high-grade serous ovarian cancer.**
Coan M, Rampioni Vinciguerra GL, Cesaratto L, Gardenal E, Bianchet R, Dassi E, Vecchione A, Baldassarre G, Spizzo R, Nicoloso MS.
Int J Mol Sci. 2018 24; 19(9). (IF 4.183, Citations 13)

10. High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adolescents and young adults.

Scarpino S, Rampioni Vinciguerra GL, Di Napoli A, Fochetti F, Uccini S, Marchetti P, Ruco L.
Lung Cancer. 2016 Jul; 97: 95-8. (IF 4.294, Citations 27)

11. Inhibition of breast cancer local relapse by targeting p70s6 kinase activity.

Segatto I, Berton S, Sonogo M, Massarut S, D'andrea S, Perin T, Fabris L, Armenia J, Rampioni Vinciguerra GL, Lovisa S, Schiappacassi M, Colombatti A, Bristow Rg, Vecchione A, Baldassarre G, Belletti B.

J Mol Cell Biol. 2013 dec;5(6):428-31. (IF 8.432, Citations 17)

Signature